Document Detail

Patient self-injection: a new approach to administering luteinizing hormone-releasing hormone analogues.
MedLine Citation:
PMID:  11069411     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate the feasibility and advantages of self-injection of a depot dose of luteinizing hormone-releasing hormone (LHRH) analogue in patients with prostate cancer. PATIENTS AND METHODS: Twenty patients (mean age 70.9 years, range 53-85) with locally advanced or metastatic prostate cancer were recruited from urology clinics and, using a defined protocol, were taught to perform self-injection of a depot LHRH analogue (Prostap SR or Prostap 3, leuprorelin acetate, Wyeth Laboratories, Berks, UK). Patients were then followed for 1 year. RESULTS: Of the 20 patients, 11 successfully learned to use self-injection and administered injections for the duration of the study. Ten of the patients chose self-injection and continued to self-inject after the end of this study. CONCLUSIONS: This pilot study of 20 patients showed that it is feasible for a selected group of patients to be taught self-injection of an LHRH analogue, and that some patients prefer this mode of drug administration.
R Hamm; B Patel; T Whittlestone; R Persad
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  BJU international     Volume:  86     ISSN:  1464-4096     ISO Abbreviation:  BJU Int.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2001-01-10     Completed Date:  2001-02-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  840-2     Citation Subset:  IM    
Department of Urology, Derriford Hospital, Plymouth, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Feasibility Studies
Gonadotropin-Releasing Hormone / administration & dosage*,  analogs & derivatives*
Middle Aged
Pilot Projects
Prostatic Neoplasms / drug therapy*
Self Administration*
Reg. No./Substance:
33515-09-2/Gonadotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners.
Next Document:  Vaginoplasty in male transsexuals using penile skin and a urethral flap.